NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Greenply Industries Maintains Strong Growth Outlook

Choice Institutional Equities has released a report on Greenply Industries, highlighting the company's positive outlook for the fiscal year 2027. Greenply Industries, commonly referred to as MTLM, is expected to continue experiencing healthy volume growth across its plywood and medium-density fiberboard (MDF) segments.

According to the report, MTLM is guiding for higher leverage in the near term to support expansion while maintaining a stable long-term balance sheet. The company's core plywood demand remains subdued, but is supported by continued market share gains from organized players. In contrast, the MDF segment continues to outperform, driven by robust industry growth and stronger margin and volume guidance. Additionally, MTLM's new growth drivers, such as PVC doors and windows, and the furniture hardware joint venture, are in scale-up mode and are expected to improve profitability over the medium term as utilization ramps up and domestic manufacturing expands.

SegmentFY27E GrowthFY28E Growth
EBITDA4.1%3.9%
PAT1.2%(-1.1)%

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The report maintains a BUY rating on MTLM with a revised target price of INR 355 per share. This revised target price is unchanged from the previous estimate, reflecting the analyst's confidence in the company's growth prospects. The analyst has also increased its estimates for EBITDA and profit after tax (PAT) growth for fiscal year 2027 and 2028, respectively.

Investor Takeaway

Investors should consider buying Greenply Industries with a target price of Rs 355.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.